摘要
冠心病是患病率高、危害性强、对人类健康造成极大威胁的临床最常见的心血管疾病之一。近年来,肠道菌群及其代谢产物与冠心病的研究逐渐深入。本文基于心与小肠相表里的中医基础理论,从心与小肠的关系对冠心病进行辩证。通过发掘云南罗氏调气理血学术流派治疗冠心病的经验方——生脉冠心方的药物单体、药对、合方对肠道菌群及其代谢产物的研究进展,为本方通过影响肠道菌群治疗冠心病提供理论依据,为继承发展名医经验提供一份助力。Coronary heart disease is one of the most common clinical cardiovascular diseases with high incidence, strong harm, and great threat to human health. In recent years, research on the relationship between gut microbiota and its metabolites with coronary heart disease has gradually deepened. This article is based on the basic theory of traditional Chinese medicine that the heart and small intestine are interrelated, and dialectically treats coronary heart disease from the relationship between the heart and small intestine. By exploring the experience of the Yunnan Roche Qi regulating and Blood regulating academic school in treating coronary heart disease—the research progress of the drug monomers, drug pairs, and combination formulas of Shengmai Guanxin Formula on gut microbiota and its metabolites, this study provides a theoretical basis for our formula to treat coronary heart disease by influencing gut microbiota, and provides assistance for inheriting and developing the experience of famous doctors.
出处
《临床医学进展》
2025年第4期2362-2369,共8页
Advances in Clinical Medicine
基金
云南省教育厅科学研究基金项目(2023Y0478)。
